Trials / Completed
CompletedNCT01013389
Actifuse ABX Versus INFUSE in Posterolateral Instrumented Lumbar Fusion (PLIF) With Interbody Fusion
A Prospective, Randomised Study Comparing the Use of Actifuse (Trademark)ABX Synthetic Bone Substitute With INFUSE (Registrered Trademark) in Patients Requiring Posterolateral Instrumented Lumbar Fusion With Interbody Fusion
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Baxter Healthcare Corporation · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this clinical trial is to evaluate the success rates of Actifuse ABX and INFUSE in achieving bone fusion. The secondary objective of this clinical trial is to assess clinical outcome measurements.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Actifuse ABX | bone substitute used for posterolateral instrumented lumbar fusion with interbody fusion |
| PROCEDURE | INFUSE, plus master granules (MGG) | bone substitute in posterolateral instrumented lumbar fusion with interbody fusion |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2009-11-13
- Last updated
- 2017-04-05
Locations
2 sites across 2 countries: Australia, Netherlands
Source: ClinicalTrials.gov record NCT01013389. Inclusion in this directory is not an endorsement.